Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
70.00    0.00 (0.00%)
Bid:
69.00
Ask:
71.00
Spread: 2.00 (2.899%)
Market Cap: £318.58m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Final Results

12 Dec 2008 12:06

RNS Number : 0481K
Avacta Group PLC
12 December 2008
 



Avacta Group plc

Audited Results for the year to 31 July 2008

On 4 November 2008, Avacta Group plc ("Avacta", the "Group" or the "Company") announced its preliminary results for the year to 31 July 2008. The preliminary results included intangible assets of £7,144,000 and an other reserve of £1,834,000 reflecting the application of reverse acquisition accounting of the transaction whereby Avacta Limited reversed into Avacta Group plc (formerly Readybuy plc) during August 2006. Upon conversion from accounting under United Kingdom Generally Accepted Accounting Practice to International Financial Reporting Standards as adopted by the European Union, it is possible to recognise a different treatment of this transaction within the financial statements, which the Directors believe to be beneficial.

There is no impact on the income statement or the cash flows of the Group in either the current or comparative accounting period

Accordingly, the consolidated balance sheet of the Group has been adjusted from that included within the Preliminary Announcement to reflect this revised treatment resulting in goodwill of £3,563,000 that had been previously recognised within the intangible assets of £7,144,000 now being recognised within the other reserveThe adjusted consolidated balance sheet is included within this announcement. 

There are no other changes to the Preliminary Announcement.

The Company's full Annual Report & Accounts are available on its website at www.avacta.com

Enquiries:

Avacta Group plc

087 0835 4367

Alastair Smith, Chief Executive Officer

Tim Sykes, Chief Financial Officer

Daniel Stewart & Company plc

020 7776 6550

Lindsay Mair / Charlotte Stranner

Novum Securities Limited

020 7562 4700

Henry Turcan

Haggie Financial LLP

020 7417 8989

Nicholas Nelson / Kathy Boate

   

   Consolidated Balance Sheet as at 31 July 2008

2008

2007

£000

£000

Non-current assets

Property, plant & equipment

290

148

Intangible assets

3,581

-

-------------

------------

3,871

148

-------------

------------

Current assets

Trade and other receivables

92

170

Income taxes

84

-

Cash and cash equivalents

1,097

2,527

-------------

------------

1,273

2,697

-------------

------------

Total assets

5,144

2,845

-------------

------------

Current liabilities

Trade and other payables

(234)

(164)

Finance lease obligations

(11)

(11)

-------------

------------

(245)

(175)

-------------

------------

Non-current liabilities

Finance lease obligations

(30)

(41)

-------------

------------

(30)

(41)

-------------

------------

Total liabilities

(275)

(216)

-------------

------------

Net assets

4,869

2,629

-------------

------------

Equity attributable to equity holders of the Company

Called up share capital

900

856

Share premium account

6,524

4,882

Other reserve

(1,729)

(1,729)

Capital reserve

1,899

-

Retained earnings

(2,725)

(1,380)

-------------

------------

Total equity

4,869

2,629

-------------

------------

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR EAAAAFEDPFFE
Date   Source Headline
29th Jun 20217:00 amRNSAffiDX Lateral Flow Test Detects Delta Variant
28th Jun 202112:13 pmRNSResult of AGM
21st Jun 20212:05 pmRNSSecond Price Monitoring Extn
21st Jun 20212:00 pmRNSPrice Monitoring Extension
21st Jun 20217:00 amRNSAffiDX Lateral Flow Test Distribution Agreement
15th Jun 20218:00 amRNSIssue of Equity and Total Voting Rights
11th Jun 20212:05 pmRNSSecond Price Monitoring Extn
11th Jun 20212:00 pmRNSPrice Monitoring Extension
11th Jun 202111:07 amRNSRegistration of AffiDX Lateral Flow Test in EU
9th Jun 20219:08 amRNSHolding(s) in Company
7th Jun 20217:00 amRNSMHRA Confirms Registration of Lateral Flow Test
1st Jun 20217:00 amRNSUpdate on Lateral Flow Test Regulatory Submissions
28th May 20217:00 amRNSResponse to speculation
25th May 202110:00 amRNSPosting of Annual Report and Notice of AGM
10th May 202110:36 amRNSAffiDX SARS-CoV-2 Antigen Lateral Flow Test Update
6th May 20217:00 amRNSChange of Nominated Adviser
30th Apr 202112:37 pmRNSIssue of Equity
28th Apr 20215:18 pmRNSIssue of Equity
28th Apr 20214:41 pmRNSSecond Price Monitoring Extn
28th Apr 20214:36 pmRNSPrice Monitoring Extension
22nd Apr 20217:00 amRNSFinal Results
20th Apr 202111:05 amRNSSecond Price Monitoring Extn
20th Apr 202111:00 amRNSPrice Monitoring Extension
20th Apr 20217:00 amRNSClinical validation of AffiDX Lateral Flow Test
15th Apr 20214:36 pmRNSPrice Monitoring Extension
13th Apr 20217:00 amRNSNotice of Results and Investor Presentation
12th Apr 20211:30 pmRNSIssue of Equity
6th Apr 20217:00 amRNSDistribution Agreement with ABCAM plc
25th Mar 20213:01 pmRNSDirectorate Change
16th Mar 20215:08 pmRNSIssue of Equity
15th Mar 20215:22 pmRNSIssue of Equity
9th Mar 20217:00 amRNSDiagnostic Licensing Deal with Biokit
8th Mar 20217:00 amRNSRapid Antigen Test Detects SARS-CoV-2 Variants
3rd Mar 20215:14 pmRNSElectronic Communications with Shareholders
24th Feb 20217:00 amRNSBusiness Update
22nd Feb 20217:00 amRNSRe: Press Speculation
18th Feb 20217:00 amRNSPhase I CTA for AVA6000 Approved by MHRA
16th Feb 20219:05 amRNSSecond Price Monitoring Extn
16th Feb 20219:00 amRNSPrice Monitoring Extension
16th Feb 20217:00 amRNSResults of Initial Evaluation of SARS-CoV-2 LFT
8th Feb 20217:00 amRNSCommercial Partnership with Mologic
2nd Feb 20218:30 amRNSIssue of Equity
1st Feb 20217:00 amRNSAffyXell $7.3 Million Series A Financing
29th Jan 202111:00 amRNSIssue of Equity
28th Jan 20217:00 amRNSCollaboration Agreement with Bruker
7th Jan 20217:00 amRNSLicense Agreement with POINT Biopharma Inc.
5th Jan 202111:05 amRNSSecond Price Monitoring Extn
5th Jan 202111:00 amRNSPrice Monitoring Extension
23rd Dec 20207:00 amRNSSubmission of CTA for AVA6000 Pro-doxorubixin
21st Dec 20207:00 amRNSLicense Agreement with Astrea Bioseparations

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.